#clinical trial

Positive results announced by Madrigal Pharmaceuticals could potentially lead to the first drug approval for fatty liver disease.

Black people make up only 6% and Latino people make up 5% of participants in cirrhosis trials in the United States.

A study found that only 43% of clinical trials reported race and ethnicity. The FDA issued guidance to address these inequalities.

“Over 40% of the vulnerable population in the U.S. lives within 5 miles of a CVS Pharmacy location, so we have a chance to engage them.”

Certain racial/ethnic groups and older people aren’t being adequately represented and trial reporting guidelines aren’t being followed.

The drugs naltrexone and bupropion are currently approved for other indications.

The vaccine demonstrated 95% efficacy in an ongoing Phase III trial.

The front-runner coronavirus vaccine appears to protect people from symptomatic disease.

New Yorker Alejandrina Peña had hepatitis C—until a great doctor and powerful new treatment gave her a fresh start.

The best-performing combo, firsocostat and cilofexor, showed benefits despite missing the main study endpoint.

The study asks whether certain approved therapies or late-stage investigational drugs show promise against COVID-19.

The HIV protease inhibitor combination did not speed recovery or reduce the risk of death in a large study.

A daily dose of the growth factor analogue administered over 24 weeks also aided in NASH resolution.

More diversity would help doctors determine whether coronavirus treatments and vaccines will work for all population groups.

A fifth of the worldwide population with fatty liver disease consists of lean people.